Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Announces Pricing of Approximately $5.0 Million Registered Direct Offering

GlobeNewswire September 20, 2019

Aeterna Zentaris Announces Director Change

GlobeNewswire August 20, 2019

Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results

GlobeNewswire August 13, 2019

Aeterna Zentaris Provides Corporate Update

GlobeNewswire June 6, 2019

Aeterna Zentaris Announces Results of Annual and Special Shareholders' Meeting

GlobeNewswire May 8, 2019

Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results

GlobeNewswire May 7, 2019

50 Biggest Movers From Yesterday

Benzinga.com  April 12, 2019

The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

Benzinga.com  April 5, 2019

The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Benzinga.com  April 2, 2019

62 Biggest Movers From Friday

Benzinga.com  April 1, 2019

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results

GlobeNewswire March 26, 2019

Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019

GlobeNewswire March 19, 2019

IIROC Trade Resumption - AEZS

Canada NewsWire March 13, 2019

The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Benzinga.com  March 13, 2019

Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor

GlobeNewswire March 12, 2019

IIROC Trading Halt - AEZS

Canada NewsWire March 12, 2019

The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Benzinga.com  February 5, 2019

58 Biggest Movers From Yesterday

Benzinga.com  January 17, 2019

Aeterna Zentaris Receives European Marketing Clearance for Macimorelin

GlobeNewswire January 16, 2019

Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore

GlobeNewswire December 21, 2018